Clover Corporation (ASX: CLV) has reported a strong H1 FY26, driven by significant gross margin expansion, and the company has maintained its FY26 revenue guidance of $92m to $96m.
Revenue increased 17% to $44.1m in 1H FY26, up from $37.6m in 1H FY25, driven by recovery across Europe and ANZ, alongside key customer growth.
Gross margin significantly improved to 35.6% from 27.1% in the prior year period, an increase of 850 basis points.
This was attributed to a favourable customer and product mix, coupled with strong manufacturing performance.
EBITDA rose to $6.9m from $4.3m in 1H FY25, and Net Profit After Tax (NPAT) increased to $4.2m from $2.4m in 1H FY25.
Maintained FY26 Revenue Guidance
Full-year FY26 revenue guidance remains between $92m and $96m.
Management expects positive 1H momentum to carry into a stronger 2H FY26, contingent on stable geopolitical conditions and supply chains.
Growth drivers include improved trading conditions, product mix optimisation, and manufacturing efficiencies.
Customer diversification across broader human nutrition segments, including seniors, toddlers, and adult nutrition, also aims to reduce reliance on any single market.
Operational and Production Updates
The Melody Dairies joint venture in New Zealand, 43.9% owned by Clover, demonstrated improved plant utilisation and efficiency.
This contributed to Clover’s manufacturing requirements and the joint venture meeting revised banking covenants.
Ecuador operations remained stable, with crude fish oil extraction providing approximately 30% of tuna oil inputs.
Negotiations are ongoing to secure additional tuna head supply.
A deliberate inventory build of crude and refined oils occurred, impacting working capital.
This build was undertaken against strong customer forecasts.
Product Development and Regulatory Progress
CholineXcel development continues, with customer samples and packaging optimisation progressing.
Shelf-life testing is ongoing, and non-infant product trials commenced in Q1 FY26. A PCT filing for its IP is expected in July 2026.
The Premneo regulatory pathway is advancing.
An expert panel has acknowledged product benefits with no safety issues raised, the EU opinion is in finalisation following fact-checking, and a clinical trial is planned in India.
Regulatory assistance for Singapore and Canada is also progressing.
New packaging lines for oil pouches have been implemented to support various oil pouch formats and customer requirements.
Sales of ARA (Omega 6) are projected to grow in 2H FY26, supported by distributor expansion.
Outlook and Risks
Clover Corporation has demonstrated strong first-half performance with significant margin expansion and maintained revenue guidance, supported by operational efficiencies and product development progress.
However, the company's outlook remains contingent on stable geopolitical conditions and supply chains, with potential risks in working capital management due to inventory levels.
Investors should also note the inherent regulatory risks associated with product approvals and the timing and execution risks for new product launches and clinical trials.
Commodity price fluctuations and broader supply chain stability remain crucial factors for the business.
There is also exposure to foreign exchange movements, and sustained high inventory levels could pressure cash conversion if demand forecasts soften.
